Navigation Links
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
Date:12/13/2007

MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edinburgh, U.K. ALN-RSV01 is an RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading cause of pediatric hospitalization in the U.S. and a prevalent infection in immune-compromised adults. RSV currently does not have a viable treatment option. The Phase I study represents the first-ever clinical study of an RNAi therapeutic administered via inhalation.

"With the flexibility of the eFlow platform, we are collaborating with a number of pharmaceutical companies to develop new respiratory therapies that are delivered to the lungs in a faster, more effective manner. We hope that working with Alnylam on a treatment for RSV will open up a new treatment option to meet this unmet need," said Geoff Hunziker, President of eFlow LLC.

Alnylam's Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation via nebulizer. All major objectives of the trial were met, including definition of a safe and well-tolerated dose and regimen for advancement of ALN-RSV01 into further Phase II development. Importantly, data showed that the efficiency of delivery of ALN-RSV01 delivered via inhalation, as measured by plasma levels, was significantly greater in humans than observed pre-clinically.

Respiratory syncytial virus (RSV) is a highly contagious virus that causes infections in the upper and lower respiratory tract associated with predictable seasonal outbreaks worldwide. RSV infection is the most common cause for infant hospitalization (more than 100,000 hospitalizations annually in the U.S.), and the virus is a significant pathogen in the elderly. The RNAi therapeutic agent ALN-RSV01 is a small interfering ribonucleic acid (siRNA) targeting the messenger RNA of the RSV N gene to prevent viral replication. To deliver ALN-RSV01 to the site of infection, the siRNA is being administered as an aerosol in a highly efficient pulmonary delivery system, the optimized eFlow(R) electronic nebulizer, with high drug output, optimized droplet size, and low residual drug loss.

About eFlow

eFlow, an electronic, portable nebulizer, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily inhaled treatments.

About PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at http://www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
3. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. LOreal Paris Celebrates Ten Years of Hope and Healing
6. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
7. Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E
8. Laser Energetics Delivers BrightStar(TM) Alexandrite Laser to Fortune 50 Defense Company
9. Lilly Delivers Strong Third-Quarter Results
10. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
11. E.D.G.E. in Leadership Study Delivers First-Ever Data on Executive Women in Pharmaceutical and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... ... 28, 2017 , ... From April 30 to May 3, ... will host industry leaders for the annual spring Convention & Expo, called Momentum ... adapt to the issues currently affecting urgent care and on-demand healthcare. , “Momentum ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, ... through its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging ... the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract ...
(Date:4/28/2017)... MEMPHIS, Tenn. (PRWEB) , ... April 28, 2017 , ... ... VeinViewer® system, today announced an alliance with B. Braun Medical Inc. , a ... central role in patient care with as many as 90 percent of hospital patients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: